MedTrace Logo

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

NCT00721409 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2019-11-04

Study results available
· View outcomes & findings →

Summary

The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer

Conditions

Interventions

DRUG

PD 0332991

125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles

DRUG

letrozole

2.5 mg/d tablets orally on a continuous regimen

DRUG

letrozole

2.5 mg/d tablets orally on a continuous regimen

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-15
Primary Completion
2013-11-29
Completion
2017-12-20

Countries

  • United States
  • Canada
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00721409 on ClinicalTrials.gov